IMPORTANT ROADRUNNER TRANSPORTATION SYSTEMS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Eastern District of Wisconsin against Roadrunner Transportation Systems, Inc

NEW YORK, Feb. 09, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Roadrunner Transportation Systems, Inc. (NYSE:RRTS) (“Roadrunner” or the “Company”) on behalf of purchasers of the Company’s securities between May 8, 2014 and January 30, 2017, inclusive (the “Class Period”), in the United States District Court for the Eastern District of Wisconsin.

Investors who have incurred losses in shares of Roadrunner Transportation Systems, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you have purchased shares of Roadrunner Transportation Systems, Inc. within the class period and would like to assist with the litigation process, you may, no later than April 3, 2017, request that the Court appoint you lead plaintiff of the proposed class.

The filed complaint alleges that Roadrunner and certain of its executive officers made a series of materially false and misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects to investors during the Class Period. Specifically, the defendants are alleged to have made false and misleading statements and/or failed to disclose that: (1) the Company lacked effective internal controls over financial reporting; (2) the Company’s financial statements dating back to the beginning of 2014 overstated the estimated results of operations; (3) the Company’s financial statements contained errors relating to unrecorded expenses from unreconciled balance sheet accounts including cash, driver and other receivables, and linehaul and other driver payables; and (4) the Company’s financial statements dating back to the beginning of 2014 were not reliable.

On January 30, 2017, Roadrunner disclosed that, as a result of “information obtained to date in connection with an ongoing investigation” into the Company’s accounting, certain of Roadrunner’s previously issued financial statements should no longer be relied upon due to misstatements. Additionally, the Company reported that “Roadrunner has identified various accounting errors that it currently estimates will require prior period adjustments to Roadrunner’s results of operations of between $20 million and $25 million.”

Further, Roadrunner reported that it would need to record a goodwill impairment charge, estimated “in the range of $175 million to $200 million,” in its upcoming quarterly financial report.

On this news, shares of the Company’s stock fell $3.62 per share, or over 31%, to close on January 31, 2017 at $7.92 per share, on unusually heavy trading volume.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

Follow the firm and learn about newly filed cases on Twitter and Facebook.

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP 
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774